Autophagy induced by conventional chemotherapy mediates tumor cell sensitivity to immunotherapy

Cancer Research

Volumn 72, Issue 21, 2012, Pages 5483-5493

  Ramakrishnan, Rupal ^a   Huang, Chun ^a,d   Cho, Hyun Il ^a   Lloyd, Mark ^a   Johnson, Joseph ^a   Ren, Xiubao ^d   Altiok, Soner ^a,b   Sullivan, Daniel ^a,b   Weber, Jeffrey ^a   Celis, Esteban ^a,b,c   Gabrilovich, Dmitry I ^a,b,c  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^b Departments of Oncologic Sciences   (United States)

^c UNIVERSITY OF SOUTH FLORIDA   (United States)

^d TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOXORUBICIN; MELPHALAN; PACLITAXEL; SHORT HAIRPIN RNA; SOMATOMEDIN B RECEPTOR; TOPOTECAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; AUTOPHAGY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PATIENT; CELL SURFACE; CLINICAL ARTICLE; DRUG DOSE ESCALATION; DRUG EFFICACY; ENZYME REGULATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYSIS; MOLECULAR DYNAMICS; MOUSE; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOPHAGY; BLOTTING, WESTERN; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; DRUG THERAPY; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOTHERAPY; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICROSCOPY, CONFOCAL; NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTOR, IGF TYPE 2; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; UP-REGULATION;

EID: 84868226504     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-12-2236     Document Type: Article

References (45)

1. Gribben JG, Ryan DP, Boyajian R, Urban RG, Hedley ML, Beach K, et al. Unexpected association between induction of immunity to the universal tumor antigen CYP1B1 and response to next therapy. Clin Cancer Res 2005;11:4430-6.
2. Antonia SJ, Mirza N, Fricke I, Chiappori A, Thompson P, Williams N, et al. Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer. Clin Cancer Res 2006;12(3 Pt 1):878-87.
3. Arlen PM, Gulley JL, Parker C, Skarupa L, Pazdur M, Panicali D, et al.A randomized phase II study of concurrent docetaxel plus vaccine versus vaccine alone in metastatic androgen-independent prostate cancer. Clin Cancer Res 2006;12:1260-9.
4. Schlom J, Arlen PM, Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res 2007;13:3776-82.
5. Wheeler CJ, Das A, Liu G, Yu JS, Black KL. Clinical responsivenessof glioblastoma multiforme to chemotherapy aftervaccination. Clin Can-cer Res 2004;10:5316-26.
6. Ramakrishnan R, Antonia S, Gabrilovich DI. Combined modalityimmu- notherapy and chemotherapy: a new perspective. Cancer Immunol Immunother 2008;57:1523-9.
7. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13: 1050-9.
8. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008;8:59-73.
9. Green DR, Ferguson T, Zitvogel L, Kroemer G. Immunogenic and tolerogenic cell death. Nat Rev Immunol 2009;9:353-63.
10. Shurin GV, Tourkova IL, Kaneno R, Shurin MR. Chemotherapeutic agents in noncytotoxic concentrations increase antigen presentation by dendritic cells via an IL-12-dependent mechanism. J Immunol 2009;183:137-44.
11. Tanaka H, Matsushima H, Nishibu A, Clausen BE, Takashima A. Dual therapeutic efficacy ofvinblastine asaunique chemotherapeutic agent capable of inducing dendritic cell maturation. Cancer Res 2009;69: 6987-94.
12. Bergmann-Leitner ES, Abrams SI. Treatment of human colon carci-noma cell lines with anti-neoplastic agents enhances their lytic sen-sitivity to antigen-specific CD8+ cytotoxic T lymphocytes. Cancer Immunol Immunother 2001;50:445-55.
13. Emens LA, Jaffee EM. Leveraging the activity oftumorvaccines with cytotoxic chemotherapy. Cancer Res 2005;65:8059-64.
14. Behl D, Porrata LF, Markovic SN, Letendre L, Pruthi RK, Hook CC, et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 2006;20:29-34.
15. Liseth K, Ersvaer E, Hervig T, Bruserud O. Combination of intensive chemotherapy and anticancer vaccines in the treatment of human malignancies: the hematological experience. J Biomed Biotechnol 2010;2010:692097.
16. Jaffee EM, Hruban RH, Biedrzycki B, Laheru D, Schepers K, Sauter PR, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol 2001;19:145-56.
17. Ives NJ, Stowe RL, Lorigan P, Wheatley K. Chemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2, 621 patients. J Clin Oncol 2007;25:5426-34.
18. Ramakrishnan R, Assudani D, Nagaraj S, Hunter T, Cho HI, Antonia S, et al. Chemotherapy enhances tumor cell susceptibility to CTL-medi-ated killing during cancer immunotherapy in mice. J Clin Invest 2010;120:1111-24.
19. Diaz E, Pfeffer SR. TIP47: a cargo selection device for mannose 6-phosphate receptortrafficking. Cell 1998;93:433-43.
20. Ghosh P, Kornfeld S. The GGA proteins: key players in protein sorting at the trans-Golgi network. Eur J Cell Biol 2004;83:257-62.
21. Ghosh P, Dahms N, Kornfeld S. Mannose 6-phosphate receptros: new twists in the tale. Nat Rev Mol Cell Biol 2003;4:202-12.
22. Motyka B, Korbutt G, Pinkoski MJ, Heibein JA, Caputo A, Hobman M, et al. Mannose 6-phosphate/insulin-like growth factor II receptor is a death receptor for granzyme B during cytotoxic T cell-induced apo-ptosis. Cell 2000;103:491-500.
23. Trapani JA, Sutton VR, Thia KY, Li YQ, Froelich CJ, Jans DA, et al. A clathrin/dynamin- and mannose-6-phosphate receptor-independent pathway for granzyme B-induced cell death. J Cell Biol 2003;160: 223-33.
24. Veugelers K, Motyka B, Goping IS, Shostak I, Sawchuk T, Bleackley RC. Granule-mediated killing by granzyme B and perforin requires a mannose 6-phosphate receptor and is augmented by cell surface heparan sulfate. Mol Biol Cell 2006;17:623-33.
25. Dressel R, Raja SM, Honing S, Seidler T, Froelich CJ, von Figura K, et al. Granzyme-mediated cytotoxicity does not involve the man-nose 6-phosphate receptors on target cells. J Biol Chem 2004;279: 20200-10.
26. Bolitho P, Voskoboinik I, Trapani JA, Smyth MJ. Apoptosis induced by the lymphocyte effector molecule perforin. Curr Opin Immunol 2007;19:339-47.
27. Cho HI, Lee YR, Celis E. Interferon gamma limits the effectiveness of melanoma peptide vaccines. Blood 2011;117:135-44.
28. Notte A, Leclere L, Michiels C. Autophagy as a mediator of chemo-therapy-induced cell death in cancer. Biochem Pharmacol 2011;82: 427-34.
29. White E, Di Paola RS. The double-edged sword of autophagy modu-lation in cancer. Clin Cancer Res 2009;15:5308-16.
30. Amaravadi RK, Lippincott-Schwartz J, Yin XM, Weiss WA, Takebe N, Timmer W, et al. Principles and current strategiesfortargeting autop-hagy for cancer treatment. Clin Cancer Res 2011;17:654-66.
31. Hayashi S, Yamamoto A, You F, Yamashita K, Ikegame Y, Tawada M, et al. The stent-eluting drugs sirolimus and paclitaxel suppress healing of the endothelium by induction of autophagy. Am J Pathol 2009;175:2226-34.
32. Ciuffreda L, Di Sanza C, Incani UC, Milella M. The m TOR pathway: a new target in cancer therapy. Curr Cancer Drug Targets 2010;10: 484-95.
33. Zitvogel L, Kepp O, Kroemer G. Immune parameters affecting the efficacy of chemotherapeutic regimens. Nat Rev Clin Oncol 2011;8: 151-60.
34. Zitvogel L, Kepp O, Kroemer G. Decoding cell death signals in inflam-mation and immunity. Cell 2010;140:798-804.
35. Yu B, Kusmartsev S, Cheng F, Paolini M, Nefedova Y, Sotomayor E, et al. Effective combination of chemotherapy and dendriticcell admin-istration for the treatment of advanced-stage experimental breast cancer. Clin Cancer Res 2003;9:285-94.
36. Turcotte S, Rosenberg SA. Immunotherapy for metastatic solid cancers. Adv Surg 2011;45:341-60.
37. Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C. Whitepaperon adoptivecell therapyforcancerwithtumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res 2011;17:1664-73.
38. Klebanoff CA, Acquavella N, Yu Z, Restifo NP. Therapeutic cancer vaccines: are we there yet? Immunol Rev 2011;239:27-44.
39. Brown J, Jones EY, Forbes BE. Interactions of IGF-II with the IGF2R/ cation-independent mannose-6-phosphate receptor mechanism and biological outcomes. Vitam Horm 2009;80:699-719.
40. Gozuacik D, Kimchi A. Autophagy as a cell death and tumor suppres-sor mechanism. Oncogene 2004;23:2891-906.
41. Shintani T, Klionsky DJ. Autophagy in health and disease: a double-edged sword. Science 2004;306:990-5.
42. Amaravadi RK, Thompson CB. The roles of therapy-induced autop-hagy and necrosis in cancer treatment. Clin Cancer Res 2007;13: 7271-9.
43. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancerimmune responses induced by chemotherapeutic agents in mice. Science 2011;334:1573-7.
44. Noman MZ, Janji B, Kaminska B, Van Moer K, Pierson S, Przanowski P, et al. Blocking hypoxia-induced autophagy in tumors restores cyto-toxic T-cell activity and promotes regression. Cancer Res 2011;71: 5976-86.
45. Amaravadi R. Autophagy in tumor immunity. Science 2011;334: 1501-2.